H D I N S I G H T S
HD Insights, Vol. 10 10
H D I N S I G H T S
T M
T H A N K S L U N D B E C K F O R I T S
G E N E R O U S S U P P O R T
Copyright © Huntington Study Group 2015. All rights reserved.
Clinical Trials, cont...
To update or add a clinical trial, please e-mail editor@hdinsights.org.
Sources: www.clinicaltrials.gov and apps.who.int/trialsearch/
SPONSOR STUDY
NAME/
IDENTIFIER
STUDY
AGENT
PHASE
PRINCIPAL
INVESTIGATOR,
CONTACT
DESIGN TRIAL
LENGTH
SITES STATUS
Auspex
Pharmaceuticals
FIRST-HD
SD-809
Extended
Release
III
Samuel Frank, MD
Huntington Study
Group: 800-487-7671
Randomized double-blind study to determine
whether SD-809 ER tablets are effective in the
treatment of chorea associated with HD. To be
followed by an open-label, long-term safety
study
12 weeks
7 total -
United
States
Study
complete, top
line results
released
Auspex
Pharmaceuticals
ARC-HD
SD-809
Extended
Release
III
Samuel Frank, MD
Huntington Study
Group: 800-487-7671
Open-label, long-term safety study of SD-809 ER
58 weeks
7 total -
United
States
Enrollment
complete,
study ongoing
Assistance
Publique -
Hôpitaux de
Paris
REVHD
Resveratrol
III
Tiffany Monier, MS
+33 1 57 27 42 22
Randomized, placebo-controlled study to
evaluate the therapeutic potential of Resveratrol
on caudate volume in HD patients, using
volumetric MRI.
1 year
1 total -
France
Not yet
recruiting
Assistance
Publique -
Hôpitaux de
Paris
NEUROHD
Olanzapine,
Tetrabenazine,
and Tiapride
III
Anne-Catherine
Bachoud Levi, PhD
+33 (0)1 49 81 23 01
Randomized controlled study to compare the
beneficial and adverse effects of 3 different
neuroleptics in HD
1 year
1 total -
France
Currently
enrolling
H D I N S I G H T S
